Chemotherapy in Recurrent Epithelial Ovarian Cancer (EOC): An Analysis of Prognostic Factors

Shamsunder, Saritha; Kumar, Lalit; Gupta, Siddhartha Dutta; Kumar, Sunesh; Bhatla, Neerja; Singh, Ritika; Kochupillai, V.

doi:10.1111/j.1447-0756.2000.tb01314.x

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…bevacizumab 5 mg/kg every 21 days immediately after paracentesis for treatment of malignant ascites [5,6] plus intravenous (intravenous injection, i.v.) monochemotherapy (cisplatin) [7], while 10 other patients were identified as been treated with i.v. monochemotherapy alone (paclitaxel, topotecan, pegylated liposomal doxorubicin, cisplatin).…”

Section: Methodsmentioning

confidence: 99%

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

Napoletano

Ruscito

Bellati

et al. 2019

JCM

View full text Add to dashboard Cite

Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of non-suppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

Napoletano

Ruscito

Bellati

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…However, more than 75% of patients develop recurrent disease, and the 5-year survival is only 20-30% [ 14 , 18 ]. An important feature of recurrent EOC is development of drug resistance; in particular, platinum resistance is strongly associated with poor prognosis [ 20 , 21 ]. A challenge is therefore to develop improved therapies that will be efficacious in both the primary and metastatic settings, specifically targeting intraperitoneal tumor deposits with the aim of preventing and treating PM.…”

Section: Introductionmentioning

confidence: 99%

MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer

et al. 2017

View full text Add to dashboard Cite

Peritoneal metastasis (PM) is an important feature of epithelial ovarian cancer (EOC) and is a frequent site of drug resistant disease recurrence, identifying PM-EOC an important clinical challenge. The MOC31PE immunotoxin targets and kills tumor cells expressing the epithelial cell adhesion molecule (EpCAM), which is highly expressed in EOC, and MOC31PE is being investigated for use in treatment of PM-EOC.The efficacy of MOC31PE treatment alone and in combination with cytotoxic drugs was investigated in two human EpCAM expressing EOC cell lines, B76 and MDHA-2774, in vitro and in corresponding mouse models mimicking PM-EOC. MOC31PE efficaciously killed tumor cells alone and showed equal or superior activity in vitro (paclitaxel, cisplatin, carboplatin) and in vivo (paclitaxel, mitomycin C) compared to the investigated cytotoxic drugs. Additive, or importantly, no antagonistic effects were observed in combination experiments.In ex vivo cell culture, the cytotoxic effect of MOC31PE was studied on freshly isolated surgical EOC samples. All investigated fresh EOC samples expressed EpCAM and MOC31PE effectively reduced cell viability in ex vivo cultures.In conclusion, these results, together with our previous preclinical and clinical experience, support development of MOC31PE for treatment of PM-EOC in combination with currently used cytotoxic drugs.

show abstract

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

Hasenburg¹,

Tong²,

Fischer³

et al. 2001

Gynecologic Oncology

View full text Add to dashboard Cite

Chemotherapy in Recurrent Epithelial Ovarian Cancer (EOC): An Analysis of Prognostic Factors

Abstract: Our study confirms the benefit of platinum based chemotherapy in recurrent EOC. Patients with platinum sensitive disease, and those responding to salvage chemotherapy benefit most.

Cited by 4 publications

References 20 publications

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer

Adenovirus-Mediated Thymidine Kinase Gene Therapy in Combination with Topotecan for Patients with Recurrent Ovarian Cancer: 2.5-Year Follow-Up

Contact Info

Product

Resources

About